ALXO
ALX Oncology Holdings Inc.
Price Chart
Latest Quote
$1.54
-0.02 (-1.28%)
Current Price
| Previous Close | $1.56 |
| Open | $1.58 |
| Day High | $1.64 |
| Day Low | $1.52 |
| Volume | 858,004 |
Stock Information
| Shares Outstanding | 134.56M |
| Total Debt | $8.51M |
| Cash Equivalents | $140.32M |
| Net Income | $-88.87M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $207.23M |
| EPS (TTM) | $-1.49 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $75.41M |
| Income | $-88.87M |
| Book/sh | $1.12 |
| Cash/sh | $1.04 |
| Employees | 43 |
Financial Ratios
| Quick Ratio | 6.95 |
| Current Ratio | 7.21 |
| Debt/Eq | 5.62 |
Returns & Margins
| ROA | -36.76% |
| ROE | -74.17% |
Ownership
| Insider Ownership | 0.92% |
| Institutional Ownership | 78.77% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.86 |
| P/B | 1.37 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $4.60 |
Technical Indicators
| SMA20 | $1.91 |
| SMA50 | $1.84 |
| SMA200 | $1.66 |
| RSI | 11.11 |
| ATR | 0.1123 |
| Shares Float | 107.02M |
| Short Float | 1.14% |
| Short Ratio | 1.42 |
| Rel Volume | 0.78 |
Performance History
| Week | -18.95% |
| Month | -26.32% |
| Quarter | -30.32% |
| 6 Months | +16.67% |
| YTD | +33.91% |
| Year | +188.39% |
| 3 Years | -76.91% |
| 5 Years | -97.28% |
| 10 Years | -94.87% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $1.54 | 858,200 |
| 2026-06-04 | $1.56 | 2,843,700 |
| 2026-06-03 | $1.67 | 710,200 |
| 2026-06-02 | $1.78 | 859,900 |
| 2026-06-01 | $1.80 | 1,015,900 |
| 2026-05-29 | $1.90 | 704,800 |
| 2026-05-28 | $1.89 | 1,132,200 |
| 2026-05-27 | $1.96 | 4,239,100 |
| 2026-05-26 | $1.93 | 2,096,500 |
| 2026-05-22 | $1.98 | 1,167,900 |
| 2026-05-21 | $1.99 | 531,200 |
| 2026-05-20 | $1.99 | 438,900 |
| 2026-05-19 | $1.96 | 629,000 |
| 2026-05-18 | $2.00 | 827,300 |
| 2026-05-15 | $2.03 | 468,100 |
| 2026-05-14 | $2.04 | 406,000 |
| 2026-05-13 | $2.03 | 565,100 |
| 2026-05-12 | $2.03 | 595,500 |
| 2026-05-11 | $2.08 | 891,800 |
| 2026-05-08 | $2.08 | 998,700 |
| 2026-05-07 | $1.87 | 652,000 |
| 2026-05-06 | $2.09 | 691,000 |
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
đ° Latest News
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
MarketBeat âĸ 2026-06-04T03:02:13Z
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-06-01T17:23:59Z
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-05-12T13:40:03Z
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-09T12:30:00Z
ALX Oncology Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T14:57:21Z
Favourable Signals For ALX Oncology Holdings: Numerous Insiders Acquired Stock
Simply Wall St. âĸ 2026-05-02T12:32:04Z
bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?
Zacks âĸ 2026-04-16T13:55:00Z
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Zacks âĸ 2026-03-18T15:10:00Z
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
Zacks âĸ 2026-03-17T14:40:00Z
IBRX Stock Jumps on Progress in NK Cell Therapy Production
Zacks âĸ 2026-03-16T17:35:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Reconciled Cost Of Revenue | - | - | - | $0 |
| Cost Of Revenue | - | - | - | $0 |
| Expenses | ||||
| Interest Expense | $1,602,000 | $1,729,000 | $1,565,000 | $238,000 |
| Total Expenses | $100,846,000 | $142,467,000 | $170,278,000 | $127,436,000 |
| Other Income Expense | $-3,211,000 | $-20,000 | $389,000 | $-22,000 |
| Other Non Operating Income Expenses | $-36,000 | $-20,000 | $389,000 | $-22,000 |
| Net Non Operating Interest Income Expense | $2,362,000 | $7,637,000 | $9,084,000 | $4,040,000 |
| Interest Expense Non Operating | $1,602,000 | $1,729,000 | $1,565,000 | $238,000 |
| Operating Expense | $100,846,000 | $142,467,000 | $170,278,000 | $127,436,000 |
| General And Administrative Expense | $23,850,000 | $26,094,000 | $28,483,000 | $29,036,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Net Interest Income | $2,362,000 | $7,637,000 | $9,084,000 | $4,040,000 |
| Interest Income | $3,964,000 | $9,366,000 | $10,649,000 | $4,278,000 |
| Normalized Income | $-98,520,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Net Income From Continuing And Discontinued Operation | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Total Operating Income As Reported | $-104,021,000 | $-142,467,000 | $-170,278,000 | $-127,436,000 |
| Net Income Common Stockholders | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Net Income | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Net Income Including Noncontrolling Interests | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Net Income Continuous Operations | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Pretax Income | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,418,000 |
| Special Income Charges | $-3,175,000 | $0 | $0 | $0 |
| Interest Income Non Operating | $3,964,000 | $9,366,000 | $10,649,000 | $4,278,000 |
| Operating Income | $-100,846,000 | $-142,467,000 | $-170,278,000 | $-127,436,000 |
| Gross Profit | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | - | $-2.58 | $-3.74 | $-3.03 |
| Basic EPS | - | $-2.58 | $-3.74 | $-3.03 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-96,212,000 | $-132,249,000 | $-158,404,000 | $-122,838,000 |
| Total Unusual Items | $-3,175,000 | $0 | $0 | $0 |
| Total Unusual Items Excluding Goodwill | $-3,175,000 | $0 | $0 | $0 |
| Reconciled Depreciation | $706,000 | $872,000 | $836,000 | $342,000 |
| EBITDA (Bullshit earnings) | $-99,387,000 | $-132,249,000 | $-158,404,000 | $-122,838,000 |
| EBIT | $-100,093,000 | $-133,121,000 | $-159,240,000 | $-123,180,000 |
| Diluted NI Availto Com Stockholders | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Tax Provision | $0 | $0 | $0 | $64,000 |
| Write Off | $3,175,000 | $0 | $0 | - |
| Research And Development | $76,996,000 | $116,373,000 | $141,795,000 | $98,400,000 |
| Selling General And Administration | $23,850,000 | $26,094,000 | $28,483,000 | $29,036,000 |
| Other Gand A | $8,804,000 | $9,872,000 | $9,775,000 | $10,171,000 |
| Salaries And Wages | $15,046,000 | $16,222,000 | $18,708,000 | $18,865,000 |
| Diluted Average Shares | - | $52,174,904 | $42,987,767 | $40,699,612 |
| Basic Average Shares | - | $52,174,904 | $42,987,767 | $40,699,612 |
Fetched: 2026-06-02
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $25,981,000 | $113,618,000 | $189,712,000 | $263,464,000 |
| Total Assets | $59,046,000 | $147,775,000 | $242,553,000 | $306,489,000 |
| Total Non Current Assets | $8,319,000 | $13,423,000 | $53,894,000 | $35,520,000 |
| Other Non Current Assets | $149,000 | $200,000 | $200,000 | $288,000 |
| Non Current Prepaid Assets | $804,000 | $67,000 | $7,442,000 | $8,720,000 |
| Investmentin Financial Assets | $3,494,000 | $3,524,000 | $35,411,000 | $16,699,000 |
| Current Assets | $50,727,000 | $134,352,000 | $188,659,000 | $270,969,000 |
| Other Current Assets | $20,000 | $27,000 | $5,923,000 | $4,762,000 |
| Prepaid Assets | $5,619,000 | $5,676,000 | - | - |
| Receivables | $298,000 | $892,000 | - | - |
| Accrued Interest Receivable | $298,000 | $892,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $44,790,000 | $127,757,000 | $182,736,000 | $266,207,000 |
| Cash And Cash Equivalents | $16,373,000 | $17,567,000 | $22,406,000 | $48,822,000 |
| Non Current Accounts Receivable | - | - | - | $78,000 |
| Debt | ||||
| Total Debt | $9,749,000 | $9,904,000 | $9,639,000 | $9,389,000 |
| Long Term Debt And Capital Lease Obligation | $4,532,000 | $9,469,000 | $9,639,000 | $9,389,000 |
| Long Term Debt | $4,532,000 | $9,469,000 | $9,639,000 | $9,389,000 |
| Current Debt And Capital Lease Obligation | $5,217,000 | $435,000 | $1,575,000 | $1,041,000 |
| Current Debt | $5,217,000 | $435,000 | - | - |
| Other Current Borrowings | $5,217,000 | $435,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $33,065,000 | $34,157,000 | $52,841,000 | $43,025,000 |
| Total Non Current Liabilities Net Minority Interest | $8,512,000 | $15,657,000 | $16,840,000 | $14,700,000 |
| Other Non Current Liabilities | $3,980,000 | $6,188,000 | $7,201,000 | $5,311,000 |
| Current Liabilities | $24,553,000 | $18,500,000 | $36,001,000 | $28,325,000 |
| Other Current Liabilities | $2,323,000 | $2,573,000 | $2,205,000 | $2,050,000 |
| Payables And Accrued Expenses | $12,657,000 | $10,186,000 | $27,729,000 | $22,567,000 |
| Payables | $4,914,000 | $4,646,000 | $9,134,000 | $9,723,000 |
| Accounts Payable | $4,914,000 | $4,497,000 | $8,591,000 | $8,073,000 |
| Other Payable | - | - | - | - |
| Total Tax Payable | - | - | - | - |
| Income Tax Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $25,981,000 | $113,618,000 | $189,712,000 | $263,464,000 |
| Total Equity Gross Minority Interest | $25,981,000 | $113,618,000 | $189,712,000 | $263,464,000 |
| Stockholders Equity | $25,981,000 | $113,618,000 | $189,712,000 | $263,464,000 |
| Gains Losses Not Affecting Retained Earnings | $28,000 | $275,000 | $256,000 | $-845,000 |
| Other Equity Adjustments | $28,000 | $275,000 | $256,000 | $-845,000 |
| Retained Earnings | $-722,817,000 | $-621,122,000 | $-486,272,000 | $-325,467,000 |
| Other | ||||
| Ordinary Shares Number | $54,388,022 | $53,052,912 | $49,951,989 | $40,861,386 |
| Share Issued | $54,388,022 | $53,052,912 | $49,951,989 | $40,861,386 |
| Tangible Book Value | $25,981,000 | $113,618,000 | $189,712,000 | $263,464,000 |
| Invested Capital | $35,730,000 | $123,522,000 | $199,351,000 | $272,853,000 |
| Working Capital | $26,174,000 | $115,852,000 | $152,658,000 | $242,644,000 |
| Total Capitalization | $30,513,000 | $123,087,000 | $199,351,000 | $272,853,000 |
| Additional Paid In Capital | $748,716,000 | $734,412,000 | $675,678,000 | $589,735,000 |
| Capital Stock | $54,000 | $53,000 | $50,000 | $41,000 |
| Common Stock | $54,000 | $53,000 | $50,000 | $41,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $4,356,000 | $5,306,000 | $6,067,000 | $3,708,000 |
| Current Accrued Expenses | $7,743,000 | $5,540,000 | $18,595,000 | $12,844,000 |
| Dueto Related Parties Current | $0 | $149,000 | $543,000 | $1,650,000 |
| Investments And Advances | $3,494,000 | $3,524,000 | $35,411,000 | $16,699,000 |
| Available For Sale Securities | $3,494,000 | $3,524,000 | $35,411,000 | $16,699,000 |
| Net PPE | $3,872,000 | $9,632,000 | $10,841,000 | $9,813,000 |
| Accumulated Depreciation | $-1,979,000 | $-2,077,000 | $-1,237,000 | $-403,000 |
| Gross PPE | $5,851,000 | $11,709,000 | $12,078,000 | $10,216,000 |
| Leases | $709,000 | $2,509,000 | $2,513,000 | $2,360,000 |
| Other Properties | $4,516,000 | $8,562,000 | $8,985,000 | $7,346,000 |
| Machinery Furniture Equipment | $626,000 | $638,000 | $580,000 | $510,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $28,417,000 | $110,190,000 | $160,330,000 | $217,385,000 |
| Capital Lease Obligations | - | - | $7,558,000 | $1,041,000 |
| Long Term Capital Lease Obligation | - | - | $5,983,000 | - |
| Current Capital Lease Obligation | - | - | $1,575,000 | $1,041,000 |
Fetched: 2026-06-02
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-84,354,000 | $-122,359,000 | $-131,638,000 | $-90,650,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-84,142,000 | $-121,912,000 | $-130,364,000 | $-89,223,000 |
| Cash Flow From Continuing Operating Activities | $-84,142,000 | $-121,912,000 | $-130,364,000 | $-89,223,000 |
| Operating Gains Losses | - | $10,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-212,000 | $-447,000 | $-1,274,000 | $-1,427,000 |
| Investing Cash Flow | $82,586,000 | $86,256,000 | $44,657,000 | $-235,416,000 |
| Cash Flow From Continuing Investing Activities | $82,586,000 | $86,256,000 | $44,657,000 | $-235,416,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $0 | $58,887,000 | $0 |
| Financing Cash Flow | $362,000 | $30,817,000 | $59,291,000 | $9,860,000 |
| Cash Flow From Continuing Financing Activities | $362,000 | $30,817,000 | $59,291,000 | $9,860,000 |
| Net Other Financing Charges | $1,688,000 | $29,661,000 | - | $-655,000 |
| Net Common Stock Issuance | $0 | $0 | $58,887,000 | $0 |
| Common Stock Issuance | $0 | $0 | $58,887,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-1,364,000 | $-827,000 | $-388,000 | $-388,000 |
| Interest Paid Supplemental Data | $1,259,000 | $1,387,000 | $1,177,000 | $103,000 |
| End Cash Position | $16,439,000 | $17,633,000 | $22,472,000 | $48,888,000 |
| Beginning Cash Position | $17,633,000 | $22,472,000 | $48,888,000 | $363,667,000 |
| Changes In Cash | $-1,194,000 | $-4,839,000 | $-26,416,000 | $-314,779,000 |
| Proceeds From Stock Option Exercised | $38,000 | $1,983,000 | $792,000 | $903,000 |
| Net Issuance Payments Of Debt | $-1,364,000 | $-827,000 | $-388,000 | $9,612,000 |
| Net Long Term Debt Issuance | $-1,364,000 | $-827,000 | $-388,000 | $9,612,000 |
| Long Term Debt Payments | $-1,364,000 | $-827,000 | $-388,000 | $-388,000 |
| Net Investment Purchase And Sale | $82,798,000 | $86,703,000 | $45,931,000 | $-233,989,000 |
| Sale Of Investment | $134,391,000 | $194,109,000 | $292,560,000 | $142,800,000 |
| Purchase Of Investment | $-51,593,000 | $-107,406,000 | $-246,629,000 | $-376,789,000 |
| Net PPE Purchase And Sale | $-212,000 | $-447,000 | $-1,274,000 | $-1,427,000 |
| Purchase Of PPE | $-212,000 | $-447,000 | $-1,274,000 | $-1,427,000 |
| Change In Working Capital | $336,000 | $-12,430,000 | $8,297,000 | $9,850,000 |
| Change In Other Current Liabilities | $-1,910,000 | $-2,071,000 | $-2,353,000 | $-977,000 |
| Change In Other Current Assets | $-686,000 | $7,375,000 | $1,366,000 | $750,000 |
| Change In Payables And Accrued Expense | $2,274,000 | $-17,042,000 | $10,575,000 | $11,553,000 |
| Change In Accrued Expense | $2,002,000 | $-12,624,000 | $11,224,000 | $7,027,000 |
| Change In Payable | $272,000 | $-4,418,000 | $-649,000 | $4,526,000 |
| Change In Account Payable | $272,000 | $-4,418,000 | $-649,000 | $4,526,000 |
| Change In Prepaid Assets | $658,000 | $-692,000 | $-1,291,000 | $-1,476,000 |
| Other Non Cash Items | $1,999,000 | $2,050,000 | $1,522,000 | $1,168,000 |
| Stock Based Compensation | $12,579,000 | $27,093,000 | $26,273,000 | $23,839,000 |
| Asset Impairment Charge | $3,175,000 | $0 | - | - |
| Amortization Of Securities | $-1,242,000 | $-4,657,000 | $-6,487,000 | $-940,000 |
| Depreciation Amortization Depletion | $706,000 | $872,000 | $836,000 | $342,000 |
| Depreciation And Amortization | $706,000 | $872,000 | $836,000 | $342,000 |
| Gain Loss On Sale Of PPE | $0 | $10,000 | $0 | $0 |
| Net Income From Continuing Operations | $-101,695,000 | $-134,850,000 | $-160,805,000 | $-123,482,000 |
| Issuance Of Debt | - | $0 | $0 | $10,000,000 |
| Long Term Debt Issuance | - | $0 | $0 | $10,000,000 |
| Income Tax Paid Supplemental Data | - | - | $0 | $0 |
| Net Intangibles Purchase And Sale | - | - | $0 | $0 |
| Purchase Of Intangibles | - | - | $0 | $0 |
| Change In Receivables | - | - | - | $0 |
Fetched: 2026-06-02